SOLID LIPID NANOPARTILCES: MODERN PROGRESS IN NOSE-TO-BRAIN TRANSDUCTION

C. SOWMYA,SURIYA PRAKAASH K. K.,ABRAR AHMED H.
DOI: https://doi.org/10.22159/ijap.2023v15i4.47897
2023-07-07
International Journal of Applied Pharmaceutics
Abstract:Solid Lipid Nanoparticles (SLNs) have gained significant attention in recent years as a promising delivery system for drugs targeting the Central Nervous System (CNS) via the Nose-To-Brain (NTB) route. The unique characteristics of SLNs, such as their small particle size, high stability, and ability to encapsulate lipophilic drugs, make them suitable for crossing the Blood Brain Barrier (BBB) and achieving targeted delivery to the brain. This has led to the development of SLNs-based formulations of drugs for neurological disorders such as Alzheimer's disease and Parkinson's disease, which are being evaluated in preclinical and clinical studies. Overall, the recent advances in SLN technology have improved these nanoparticles' stability, drug loading capacity and BBB crossing ability, making them a promising delivery system for NTB drug delivery. SLNs are composed of a solid lipid core surrounded by a surfactant coating, which allows for the encapsulation of hydrophilic and hydrophobic drugs. Additionally, we will also highlight the current challenges and future perspectives of using SLNs for NTB delivery of CNS therapeutics. Overall, this review aims to provide a comprehensive overview of the current state of the art in using SLNs for NTB delivery and to encourage further research in this field.
What problem does this paper attempt to address?